[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"sensory-neuropathy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:sensory-neuropathy":35},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,53,80],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":36,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100522123","assessment-of-laryngopharyngeal-sensation-cancer-survivor-cohort-100522123",false,"NCT06078527","Assessment of Laryngopharyngeal Sensation: Cancer Survivor Cohort","Assessment of Laryngopharyngeal Sensation in Patients With Laryngopharyngeal Disorders","Inclusion Criteria:\n\n1. Age \\\u003C=18 years.\n2. Individuals without a laryngopharyngeal disorder (health controls) or with a laryngopharyngeal disorder. Laryngopharyngeal disorder includes but is not limited to: presbylarynx, aspiration; spasmodic dysphonia; globus pharynges; vocal fold paralysis; iatrogenic injury to the larynx; muscle tension dysphonia; neurogenic dysphagia; laryngeal sensory neuropathy; and laryngopharyngeal disorders resulting from prior radiation therapy in individuals with a history of head and neck cancer who have completed radiation therapy as primary or adjuvant cancer treatment\n3. Ability and willingness to comply with study procedures.\n4. Ability to understand a written informed consent document, and the willingness to sign it.\n\nExclusion Criteria:\n\n1. Non-English speaking.\n2. Laryngopharyngeal structures are not accessible on exam.\n3. Known contraindication to any study-related procedure, or history of being unable to tolerate laryngoscopy.\n4. Vocal fold immobility or severe hypomobility on adduction.\n5. For head and neck cancer survivors only: Currently undergoing radiation therapy for head and neck cancer (i.e., primary\u002Fadjuvant radiation therapy treatment plan is not yet completed).","ALL","18 Years","85 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"NA","A previous study completed in 2022 (NCT05158179) was conducted using cohorts of healthy controls, and adults with general laryngopharyngeal disorders. This study will expand on the previous research to include a separate cohort of adults being seen in clinic for an existing laryngopharyngeal disorder resulting from previous radiation or other cancer treatments.",[27,28,29,30,31,32,33,34,35],"Presbylarynx","Aspiration","Spasmodic Dysphonia","Globus Pharyngeus","Larynx Paralysis","Laryngeal Disease","Vocal Cord Paralysis","Iatrogenic Injury","Sensory Neuropathy",[37,38,39],"Cancer survivors","Previous cancer treatment","Laryngopharyngeal disorders","NOT_YET_RECRUITING","2025-07-21",{"date":43,"type":44},"2025-07-23","ACTUAL",{"date":46,"type":21},"2025-10-01",{"date":48,"type":21},"2028-01-31",{"name":50,"class":51},"University of California, San Francisco","OTHER",1,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":60,"sex":16,"minAge":17,"maxAge":61,"enrollmentInfo":62,"targetDuration":4,"studyType":22,"phases":63,"briefSummary":64,"conditions":65,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":52},"100476429","multisensory-stimulation-to-target-sensory-loss-and-chronic-pain-in-neuropathic-patients-100476429","NCT05483816","MultiSENSory Stimulation to TArgeT Sensory Loss and ChronIc Pain in NeurOpathic PatieNts","SENSATION","for healthy:\n\n* Inclusion:\n\n  * Age 18-80\n  * Visual acuity\\>6 on Snellen visual acuity chart\n* Exclusion:\n\n  * Pregnancy\n  * Cognitive deficits (Mini Mental State Examination\\<23)\n  * Cyber-sickness\n  * Prior or current psychological diseases\n  * Pacemakers\n  * Epilepsy\n  * Claustrophobia\n  * Other MRI contraindications\n  * Unhealed fractures\n  * Unhealed wounds\n  * Cancerous growth in proximity to feet\n  * Swollen, infected or inflamed areas on feet or skin eruptions on feet such as phlebitis, thrombophlebitis or varicose veins\n\nfor patients:\n\n* Inclusion:\n\n  * Age 18-80\n  * Visual acuity\\>6 on Snellen visual acuity chart\n  * Diagnosis of peripheral neuropathy\n  * Pain in lower limbs\\>=3 cm on VAS scale\n* Exclusion:\n\n  * Pregnancy\n  * Relevant comorbidities that would affect the outcomes of the study (by judgement of physicians)\n  * Ulcers\n  * Cognitive deficits (Mini Mental State Examination\\<23)\n  * Cyber-sickness\n  * Prior or current psychological diseases\n  * Pacemakers\n  * Epilepsy\n  * Claustrophobia\n  * Other MRI contraindications\n  * Unhealed fractures\n  * Unhealed wounds\n  * Cancerous growth in proximity to feet",true,"80 Years",{"count":20,"type":21},[24],"Neuropathy is a costly and disabling health issue, which consists of a degeneration of the peripheral nerves. Even though the causes may be different, such as diabetes or amputation, the consequences for neuropathic patients are multiple and extremely debilitating. Among the alarming symptoms it implicates, chronic pain and sensory loss are among the most severe ones. Because of the loss of sensations, patients are forced to have an altered gait strategy, an impaired balance and a fivefold increased risk of falling. Furthermore, since they lose sensations and feel numbness in their extremity, they are discouraged in walking, hence leading to a sedentary lifestyle. All of this is worsened by the development of neuropathic pain, which has a high comorbidity with psychological issues, such as depression and anxiety.\n\nToday, proper treatments for neuropathic pain that exclude pharmacological solutions are still missing. This is due to the complexity of the neurobiological mechanisms underlying the origin of neuropathy, the multifaceted physical and psychological nature of pain and the lack of reliable biomarkers.\n\nThe aim of this project is to tackle the major problems connected to neuropathy thanks to non-invasive stimulation of the peripheral nervous system. The system is composed of an insole with pressure sensors that captures in real time the force exerted by the subject on the foot and couples this information with parameters of electrical stimulation. Thanks to optimal electrode placement and intensity modulation, subjects are able to perceive in real-time in a somatotopic manner (i.e., under their foot) how they are walking. The aim now is twofold: first the investigators want to couple this stimulation with Virtual Reality (VR) to develop a neuroadaptive non-invasive brain computer interface (BCI) to treat pain and secondly the investigators want to measure through fMRI scans whether the use of the sensory feedback system allows any beneficial plastic changes in the brain. Finally, the investigators want to measure through fMRI scans whether the use of the sensory feedback system allows any beneficial plastic changes in the brain.",[66,67,35,68,69],"Neuropathy","Neuropathy, Painful","Diabetic Neuropathies","Amputation","RECRUITING","2024-11-14",{"date":73,"type":44},"2024-11-18",{"date":75,"type":44},"2022-06-30",{"date":77,"type":21},"2028-02-28",{"name":79,"class":51},"ETH Zurich",{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":87,"enrollmentInfo":88,"targetDuration":4,"studyType":22,"phases":90,"briefSummary":92,"conditions":93,"keywords":95,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":4},"100530148","phase-4-ivig-in-painful-sensory-neuropathy-100530148","NCT06183008","IVIG in Painful Sensory Neuropathy","Effect of Intravenous Immunoglobulins on Painful Sensory Neuropathy Evaluated by Aggregated N-of-one Trials","Inclusion Criteria:\n\nPainful sensory neuropathy fulfilling diagnostic criteria for idiopathic small fiber neuropathy or sensory neuronopathy\n\n* Idiopathic small fiber neuropathy (all of the following)\n\n  1. Neuropathic pain (length-dependent\u002Fnon-length dependent\u002Ffocal) and at least two of the following clinical signs\n\n     1. Hypoesthesia (tactile, pinprick, or thermal)\n     2. Allodynia (tactile, dynamic, thermal, pressure)\n     3. Hyperalgesia\n     4. Aftersensation\n  2. Normal nerve conduction studies:\n  3. Reduced intra-epidermal nerve fiber density at the distal leg (IENFD) at the distal leg or Reduced thermal threshold assessed at the foot by QST\n  4. Causal investigation according to clinical guidelines has not revealed a cause of the neuropathy\n* Sensory neuronopathy (all of the following)\n\n  1. Clinical pure sensory neuropathy\n  2. A score \\>6.5 on the following\n\n     1. Ataxia in the lower or upper limb: 3.1p\n     2. Asymmetrical distribution of sensory loss: 1.7p IVIGSeN Protocol number 1.2\n     3. Sensory loss not restricted to the lower limb at full development: 2.0 p\n     4. At least 1 sensory action potential absent or 3 sensory action potentials \\\u003C30% of the lower limit of normal in the upper limbs not explained by entrapment neuropathy: 2.8p\n     5. Less than two nerves with abnormal motor nerve conduction studies in the lower limbs: 3.1p\n  3. Causal investigation according to clinical guidelines has not revealed a cause of the neuropathy\n\nPain intensity \\> 5.0 on a pain score from 0-10, lasting at least 4 weeks\n\nExclusion Criteria:\n\nParticipants are excluded from the study if any of the following criteria apply:\n\nMedical Conditions\n\n1. Previous allergic reaction to IVIG or other blood products)\n2. Selective IgA deficiency\n3. Cardiac insufficiency (NYHA III\u002FIV ie marked or severe limitation in activity due to symptoms, even during less-than-ordinary activity)\n4. Cardiac dysrhythmia requiring treatment\n5. Unstable or advanced ischemic heart disease\n6. Severe hypertension (diastolic \\>120 or systolic \\> 170)\n7. Known hyperviscosity\n8. Renal insufficiency (GFR \\\u003C 30 ml\u002Fmin\u002F1,73m2) or nephrotic syndrome\n9. Previous thromboembolic event\n10. Smoking\n11. Diabetes\n12. Prolonged immobilization\n13. Hypercoagulable state\n\n    Prior\u002FConcomitant Therapy\n14. Change of pain medication in the 30 days prior to inclusion (unchanged pain medication is allowed, provided dosages stay equal during the study)\n15. Treatment with IVIG the last 4 weeks or other ongoing immunomodulatory treatments\n16. Use of loop diuretics, Dinutuksimab beta, or Imlifidase Diagnostic assessments\n17. Predominant clinical or neurographic features of motor nerve fiber involvement Other Exclusions\n18. Females who are breastfeeding, pregnant or unwilling to practice contraception throughout the study\n19. Unable to give independent informed consent","65 Years",{"count":89,"type":21},20,[91],"PHASE4","The goal of this clinical trial is to assess effect of Intravenous immunoglobulins (antibodies) as compared to Placebo, on pain intensity in patients from 18-65 years with painful sensory neuropathy without a known cause. Effect of the treatment will be recorded by the patient in a digital diary.",[35,94],"Small Fiber Neuropathy",[96,97,98,99,100,101,102,103,104,105,106,107,108,109],"nervous system diseases","neuromuscular diseases","peripheral nervous system diseases","small fiber neuropathy","sensory neuronopathy","sensory neuropathy","IVIG","Intravenous immunoglobulin","n-of-1","Sørlandet sykehus","Sorlandet hospital","Kristiansand","polyneuropathy","Intravenous immune globulin","2023-12-13",{"date":112,"type":44},"2023-12-27",{"date":114,"type":21},"2024-02",{"date":116,"type":21},"2028-12",{"name":118,"class":119},"Sorlandet Hospital HF","OTHER_GOV"]